Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 139

1.

New landscapes and horizons in hepatocellular carcinoma therapy.

Cervello M, Emma MR, Augello G, Cusimano A, Giannitrapani L, Soresi M, Akula SM, Abrams SL, Steelman LS, Gulino A, Belmonte B, Montalto G, McCubrey JA.

Aging (Albany NY). 2020 Feb 4;12(3):3053-3094. doi: 10.18632/aging.102777. Epub 2020 Feb 4.

2.

Abilities of β-Estradiol to interact with chemotherapeutic drugs, signal transduction inhibitors and nutraceuticals and alter the proliferation of pancreatic cancer cells.

Akula SM, Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Cocco L, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Falasca M, Montalto G, Cervello M, Notarbartolo M, Gizak A, Rakus D, Libra M, McCubrey JA.

Adv Biol Regul. 2020 Jan;75:100672. doi: 10.1016/j.jbior.2019.100672. Epub 2019 Oct 18.

PMID:
31685431
3.

RAS/RAF/MEK/ERK, PI3K/PTEN/AKT/mTORC1 and TP53 pathways and regulatory miRs as therapeutic targets in hepatocellular carcinoma.

Akula SM, Abrams SL, Steelman LS, Emma MR, Augello G, Cusimano A, Azzolina A, Montalto G, Cervello M, McCubrey JA.

Expert Opin Ther Targets. 2019 Nov;23(11):915-929. doi: 10.1080/14728222.2019.1685501. Epub 2019 Nov 4. Review.

PMID:
31657972
4.

Abilities of berberine and chemically modified berberines to interact with metformin and inhibit proliferation of pancreatic cancer cells.

Akula SM, Candido S, Libra M, Abrams SL, Steelman LS, Lertpiriyapong K, Ramazzotti G, Ratti S, Follo MY, Martelli AM, Murata RM, Rosalen PL, Bueno-Silva B, Matias de Alencar S, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lin HL, Lombardi P, McCubrey JA.

Adv Biol Regul. 2019 Aug;73:100633. doi: 10.1016/j.jbior.2019.04.003. Epub 2019 Apr 21.

PMID:
31047842
5.

Effects of the MDM-2 inhibitor Nutlin-3a on PDAC cells containing and lacking WT-TP53 on sensitivity to chemotherapy, signal transduction inhibitors and nutraceuticals.

Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Bueno-Silva B, de Alencar SM, Lombardi P, Mao W, Montalto G, Cervello M, Rakus D, Gizak A, Lin HL, Libra M, Akula SM, McCubrey JA.

Adv Biol Regul. 2019 May;72:22-40. doi: 10.1016/j.jbior.2019.03.002. Epub 2019 Mar 15.

PMID:
30898612
6.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL.

J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum in: J Clin Oncol. 2019 Jun 1;37(16):1448.

PMID:
30742566
7.

Abilities of berberine and chemically modified berberines to inhibit proliferation of pancreatic cancer cells.

Abrams SL, Follo MY, Steelman LS, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Montalto G, Cervello M, Gizak A, Rakus D, Mao W, Lombardi P, McCubrey JA.

Adv Biol Regul. 2019 Jan;71:172-182. doi: 10.1016/j.jbior.2018.10.003. Epub 2018 Oct 17.

PMID:
30361003
8.

Introduction of WT-TP53 into pancreatic cancer cells alters sensitivity to chemotherapeutic drugs, targeted therapeutics and nutraceuticals.

Abrams SL, Lertpiriyapong K, Yang LV, Martelli AM, Cocco L, Ratti S, Falasca M, Murata RM, Rosalen PL, Lombardi P, Libra M, Candido S, Montalto G, Cervello M, Steelman LS, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:16-34. doi: 10.1016/j.jbior.2018.06.002. Epub 2018 Jun 28.

PMID:
29980405
9.

Roles of p53, NF-κB and the androgen receptor in controlling NGAL expression in prostate cancer cell lines.

Chappell WH, Candido S, Abrams SL, Russo S, Ove R, Martelli AM, Cocco L, Ramazzotti G, Cervello M, Montalto G, Steelman LS, Leng X, Arlinghaus RB, Libra M, McCubrey JA.

Adv Biol Regul. 2018 Aug;69:43-62. doi: 10.1016/j.jbior.2018.05.002. Epub 2018 May 18.

PMID:
29861174
10.

Metformin influences drug sensitivity in pancreatic cancer cells.

Candido S, Abrams SL, Steelman L, Lertpiriyapong K, Martelli AM, Cocco L, Ratti S, Follo MY, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Suh PG, Libra M, McCubrey JA.

Adv Biol Regul. 2018 May;68:13-30. doi: 10.1016/j.jbior.2018.02.002. Epub 2018 Feb 12.

PMID:
29482945
11.

Drug-resistance in doxorubicin-resistant FL5.12 hematopoietic cells: elevated MDR1, drug efflux and side-population positive and decreased BCL2-family member expression.

Steelman LS, Abrams SL, Ruvolo P, Ruvolo V, Cocco L, Ratti S, Martelli AM, Neri LM, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Dec 6;8(68):113013-113033. doi: 10.18632/oncotarget.22956. eCollection 2017 Dec 22.

12.

Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells.

Abrams SL, Ruvolo PP, Ruvolo VR, Ligresti G, Martelli AM, Cocco L, Ratti S, Tafuri A, Steelman LS, Candido S, Libra M, McCubrey JA.

Oncotarget. 2017 Aug 24;8(44):76525-76557. doi: 10.18632/oncotarget.20408. eCollection 2017 Sep 29.

13.

Effects of berberine, curcumin, resveratrol alone and in combination with chemotherapeutic drugs and signal transduction inhibitors on cancer cells-Power of nutraceuticals.

McCubrey JA, Abrams SL, Lertpiriyapong K, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Murata RM, Rosalen PL, Lombardi P, Montalto G, Cervello M, Gizak A, Rakus D, Steelman LS.

Adv Biol Regul. 2018 Jan;67:190-211. doi: 10.1016/j.jbior.2017.09.012. Epub 2017 Oct 3.

PMID:
28988970
14.

Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs.

McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Yang LV, Murata RM, Rosalen PL, Scalisi A, Neri LM, Cocco L, Ratti S, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Lombardi P, Nicoletti F, Candido S, Libra M, Montalto G, Cervello M.

Aging (Albany NY). 2017 Jun 12;9(6):1477-1536. doi: 10.18632/aging.101250. Review.

15.

Regulation of GSK-3 activity by curcumin, berberine and resveratrol: Potential effects on multiple diseases.

McCubrey JA, Lertpiriyapong K, Steelman LS, Abrams SL, Cocco L, Ratti S, Martelli AM, Candido S, Libra M, Montalto G, Cervello M, Gizak A, Rakus D.

Adv Biol Regul. 2017 Aug;65:77-88. doi: 10.1016/j.jbior.2017.05.005. Epub 2017 May 26. Review.

PMID:
28579298
16.

Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells.

McCubrey JA, Fitzgerald TL, Yang LV, Lertpiriyapong K, Steelman LS, Abrams SL, Montalto G, Cervello M, Neri LM, Cocco L, Martelli AM, Laidler P, Dulińska-Litewka J, Rakus D, Gizak A, Nicoletti F, Falzone L, Candido S, Libra M.

Oncotarget. 2017 Feb 21;8(8):14221-14250. doi: 10.18632/oncotarget.13991. Review.

17.

Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity-Diverse effects on cell growth, metabolism and cancer.

McCubrey JA, Rakus D, Gizak A, Steelman LS, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Yang LV, Montalto G, Cervello M, Libra M, Nicoletti F, Scalisi A, Torino F, Fenga C, Neri LM, Marmiroli S, Cocco L, Martelli AM.

Biochim Biophys Acta. 2016 Dec;1863(12):2942-2976. doi: 10.1016/j.bbamcr.2016.09.004. Epub 2016 Sep 6. Review.

18.

Roles of TP53 in determining therapeutic sensitivity, growth, cellular senescence, invasion and metastasis.

McCubrey JA, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Libra M, Cervello M, Montalto G, Yang LV, Abrams SL, Steelman LS.

Adv Biol Regul. 2017 Jan;63:32-48. doi: 10.1016/j.jbior.2016.10.001. Epub 2016 Oct 6. Review.

PMID:
27776972
19.

The therapeutic potential of mTOR inhibitors in breast cancer.

Steelman LS, Martelli AM, Cocco L, Libra M, Nicoletti F, Abrams SL, McCubrey JA.

Br J Clin Pharmacol. 2016 Nov;82(5):1189-1212. doi: 10.1111/bcp.12958. Epub 2016 May 10. Review.

20.

Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy.

Steelman LS, Fitzgerald T, Lertpiriyapong K, Cocco L, Follo MY, Martelli AM, Neri LM, Marmiroli S, Libra M, Candido S, Nicoletti F, Scalisi A, Fenga C, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Milella M, Tafuri A, Demidenko Z, Abrams SL, McCubrey JA.

Curr Pharm Des. 2016;22(16):2358-88. Review.

PMID:
26947958
21.

Novel roles of androgen receptor, epidermal growth factor receptor, TP53, regulatory RNAs, NF-kappa-B, chromosomal translocations, neutrophil associated gelatinase, and matrix metalloproteinase-9 in prostate cancer and prostate cancer stem cells.

Chappell WH, Abrams SL, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Rakus D, Gizak A, Terrian D, Steelman LS, McCubrey JA.

Adv Biol Regul. 2016 Jan;60:64-87. doi: 10.1016/j.jbior.2015.10.001. Epub 2015 Oct 9. Review.

PMID:
26525204
22.

Roles of NGAL and MMP-9 in the tumor microenvironment and sensitivity to targeted therapy.

Candido S, Abrams SL, Steelman LS, Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G, Cervello M, Polesel J, Libra M, McCubrey JA.

Biochim Biophys Acta. 2016 Mar;1863(3):438-448. doi: 10.1016/j.bbamcr.2015.08.010. Epub 2015 Aug 14. Review.

23.

Roles of EGFR and KRAS and their downstream signaling pathways in pancreatic cancer and pancreatic cancer stem cells.

Fitzgerald TL, Lertpiriyapong K, Cocco L, Martelli AM, Libra M, Candido S, Montalto G, Cervello M, Steelman L, Abrams SL, McCubrey JA.

Adv Biol Regul. 2015 Sep;59:65-81. doi: 10.1016/j.jbior.2015.06.003. Epub 2015 Jul 17. Review.

PMID:
26257206
24.

Roles of signaling pathways in drug resistance, cancer initiating cells and cancer progression and metastasis.

McCubrey JA, Abrams SL, Fitzgerald TL, Cocco L, Martelli AM, Montalto G, Cervello M, Scalisi A, Candido S, Libra M, Steelman LS.

Adv Biol Regul. 2015 Jan;57:75-101. doi: 10.1016/j.jbior.2014.09.016. Epub 2014 Oct 8.

PMID:
25453219
25.

Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention.

Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulińska-Litewka J, Basecke J, Mijatovic S, Maksimovic-Ivanic D, Montalto G, Cervello M, Fitzgerald TL, Demidenko Z, Martelli AM, Cocco L, Steelman LS, McCubrey JA.

Oncotarget. 2014 Jul 15;5(13):4603-50. Review.

26.

GSK-3 as potential target for therapeutic intervention in cancer.

McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M.

Oncotarget. 2014 May 30;5(10):2881-911. Review.

27.

Targeting breast cancer initiating cells: advances in breast cancer research and therapy.

McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Libra M, Nicoletti F, D'Assoro AB, Cocco L, Martelli AM, Steelman LS.

Adv Biol Regul. 2014 Sep;56:81-107. doi: 10.1016/j.jbior.2014.05.003. Epub 2014 May 22. Review.

PMID:
24913694
28.

Inhibition of GSK-3β activity can result in drug and hormonal resistance and alter sensitivity to targeted therapy in MCF-7 breast cancer cells.

Sokolosky M, Chappell WH, Stadelman K, Abrams SL, Davis NM, Steelman LS, McCubrey JA.

Cell Cycle. 2014;13(5):820-33. doi: 10.4161/cc.27728. Epub 2014 Jan 9.

29.

Diverse roles of GSK-3: tumor promoter-tumor suppressor, target in cancer therapy.

McCubrey JA, Davis NM, Abrams SL, Montalto G, Cervello M, Basecke J, Libra M, Nicoletti F, Cocco L, Martelli AM, Steelman LS.

Adv Biol Regul. 2014 Jan;54:176-96. doi: 10.1016/j.jbior.2013.09.013. Epub 2013 Oct 8. Review. No abstract available.

PMID:
24169510
30.

Signaling intermediates (MAPK and PI3K) as therapeutic targets in NSCLC.

Ciuffreda L, Incani UC, Steelman LS, Abrams SL, Falcone I, Curatolo AD, Chappell WH, Franklin RA, Vari S, Cognetti F, McCubrey JA, Milella M.

Curr Pharm Des. 2014;20(24):3944-57. Review.

PMID:
24138714
31.

A Phase I dose-escalation study of the VEGFR inhibitor tivozanib hydrochloride with weekly paclitaxel in metastatic breast cancer.

Mayer EL, Scheulen ME, Beckman J, Richly H, Duarte A, Cotreau MM, Strahs AL, Agarwal S, Steelman L, Winer EP, Dickler MN.

Breast Cancer Res Treat. 2013 Jul;140(2):331-9. doi: 10.1007/s10549-013-2632-9. Epub 2013 Jul 19.

PMID:
23868188
32.

Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Abrams SL, Montalto G, D'Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Cocco L, Cervello M, Martelli AM.

Leukemia. 2014 Jan;28(1):15-33. doi: 10.1038/leu.2013.184. Epub 2013 Jun 19. Review.

33.

Advances in targeting signal transduction pathways.

McCubrey JA, Steelman LS, Chappell WH, Sun L, Davis NM, Abrams SL, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Libra M, Candido S, Ligresti G, Malaponte G, Mazzarino MC, Fagone P, Donia M, Nicoletti F, Polesel J, Talamini R, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Michele M, Tafuri A, Dulińska-Litewka J, Laidler P, D'Assoro AB, Drobot L, Umezawa D, Montalto G, Cervello M, Demidenko ZN.

Oncotarget. 2012 Dec;3(12):1505-21. Review.

34.

p53 expression controls prostate cancer sensitivity to chemotherapy and the MDM2 inhibitor Nutlin-3.

Chappell WH, Lehmann BD, Terrian DM, Abrams SL, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 15;11(24):4579-88. doi: 10.4161/cc.22852. Epub 2012 Nov 27.

35.

Ectopic NGAL expression can alter sensitivity of breast cancer cells to EGFR, Bcl-2, CaM-K inhibitors and the plant natural product berberine.

Chappell WH, Abrams SL, Franklin RA, LaHair MM, Montalto G, Cervello M, Martelli AM, Nicoletti F, Candido S, Libra M, Polesel J, Talamini R, Milella M, Tafuri A, Steelman LS, McCubrey JA.

Cell Cycle. 2012 Dec 1;11(23):4447-61. doi: 10.4161/cc.22786. Epub 2012 Nov 16.

36.

Effects of ectopic expression of NGAL on doxorubicin sensitivity.

Chappell WH, Abrams SL, Montalto G, Cervello M, Martelli AM, Candido S, Libra M, Polesel J, Talamini R, Arlinghaus R, Steelman LS, McCubrey JA.

Oncotarget. 2012 Oct;3(10):1236-45.

37.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S, Malaponte G, Mazzarino MC, Fagone P, Nicoletti F, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Chiarini F, Evangelisti C, Cocco L, Martelli AM.

Oncotarget. 2012 Oct;3(10):1068-111. Review.

38.

Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment.

Chappell WH, Abrams SL, Stadelman KM, LaHair MM, Franklin RA, Cocco L, Evangelisti C, Chiarini F, Martelli AM, Steelman LS, McCubrey JA.

Adv Biol Regul. 2013 Jan;53(1):146-55. doi: 10.1016/j.jbior.2012.09.004. Epub 2012 Sep 16. No abstract available.

PMID:
23073564
39.

Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response.

McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Montalto G, Cervello M, Nicoletti F, Fagone P, Malaponte G, Mazzarino MC, Candido S, Libra M, Bäsecke J, Mijatovic S, Maksimovic-Ivanic D, Milella M, Tafuri A, Cocco L, Evangelisti C, Chiarini F, Martelli AM.

Oncotarget. 2012 Sep;3(9):954-87. Review.

40.

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies.

Ricciardi MR, Scerpa MC, Bergamo P, Ciuffreda L, Petrucci MT, Chiaretti S, Tavolaro S, Mascolo MG, Abrams SL, Steelman LS, Tsao T, Marchetti A, Konopleva M, Del Bufalo D, Cognetti F, Foà R, Andreeff M, McCubrey JA, Tafuri A, Milella M.

J Mol Med (Berl). 2012 Oct;90(10):1133-44. doi: 10.1007/s00109-012-0886-z. Epub 2012 Mar 8.

PMID:
22399013
41.

Targeting the cancer initiating cell: the ultimate target for cancer therapy.

McCubrey JA, Steelman LS, Abrams SL, Misaghian N, Chappell WH, Basecke J, Nicoletti F, Libra M, Ligresti G, Stivala F, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Bonati A, Evangelisti C, Cocco L, Martelli AM.

Curr Pharm Des. 2012;18(13):1784-95. Review.

PMID:
22394167
42.

Novel approaches to target cancer initiating cells-eliminating the root of the cancer.

McCubrey JA, Abrams SL, Umezawa K, Cocco L, Martelli AM, Franklin RA, Chappell WH, Steelman LS.

Adv Biol Regul. 2012 Jan;52(1):249-64. Review. No abstract available.

PMID:
21930143
43.

Cooperative effects of Akt-1 and Raf-1 on the induction of cellular senescence in doxorubicin or tamoxifen treated breast cancer cells.

Taylor JR, Lehmann BD, Chappell WH, Abrams SL, Steelman LS, McCubrey JA.

Oncotarget. 2011 Aug;2(8):610-26.

44.

Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Steelman LS, Navolanic P, Chappell WH, Abrams SL, Wong EW, Martelli AM, Cocco L, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, McCubrey JA.

Cell Cycle. 2011 Sep 1;10(17):3003-15. Epub 2011 Sep 1.

45.

Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy.

Sokolosky ML, Stadelman KM, Chappell WH, Abrams SL, Martelli AM, Stivala F, Libra M, Nicoletti F, Drobot LB, Franklin RA, Steelman LS, McCubrey JA.

Oncotarget. 2011 Jul;2(7):538-50.

46.

Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy.

Steelman LS, Franklin RA, Abrams SL, Chappell W, Kempf CR, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo P, Ruvolo V, Evangelisti C, Martelli AM, McCubrey JA.

Leukemia. 2011 Jul;25(7):1080-94. doi: 10.1038/leu.2011.66. Epub 2011 Apr 15. Review.

PMID:
21494257
47.

Exploiting p53 status to enhance effectiveness of chemotherapy by lowering associated toxicity.

Steelman LS, Martelli AM, Nicoletti F, McCubrey JA.

Oncotarget. 2011 Mar;2(3):109-12. No abstract available.

48.

Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway.

Martelli AM, Evangelisti C, Chappell W, Abrams SL, Bäsecke J, Stivala F, Donia M, Fagone P, Nicoletti F, Libra M, Ruvolo V, Ruvolo P, Kempf CR, Steelman LS, McCubrey JA.

Leukemia. 2011 Jul;25(7):1064-79. doi: 10.1038/leu.2011.46. Epub 2011 Mar 25. Review.

PMID:
21436840
49.

Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging.

Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F, Mazzarino MC, Donia M, Fagone P, Malaponte G, Nicoletti F, Libra M, Milella M, Tafuri A, Bonati A, Bäsecke J, Cocco L, Evangelisti C, Martelli AM, Montalto G, Cervello M, McCubrey JA.

Aging (Albany NY). 2011 Mar;3(3):192-222. Review.

50.

Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health.

Chappell WH, Steelman LS, Long JM, Kempf RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone P, Malaponte G, Mazzarino MC, Nicoletti F, Libra M, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Laidler P, Milella M, Tafuri A, Bonati A, Evangelisti C, Cocco L, Martelli AM, McCubrey JA.

Oncotarget. 2011 Mar;2(3):135-64. Review.

Supplemental Content

Loading ...
Support Center